Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

zyme produced at the 2000L capacity and the timing thereof; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD, the timetables therefore and the impact of such approvals on the company; its plans and estimated timetables for new and next- generation product filings, regulatory actions and launches, including for Mozobil, Clolar, alemtuzumab-MS, mipomersen, Genz-112638 and Synvisc-ONE and the assessment of the market potential of such products; its projected Myozyme revenues for 2008; and its anticipated growth drivers for certain products and businesses, including Genetics and Thymoglobulin. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil, Clolar, alemtuzumab-MS, mipomersen, and Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Renvela and Synvisc-ONE; Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including Myozyme produced at the 2000L scale in the US and at the 4000L scale in Europe and the timing of receipt of such approvals; Genzyme's ability to manufacture its products, including Thymoglobulin and its LSD therapies in a timely and cost effective manner and in sufficient quantities to meet demand; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10-K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Halozyme Therapeutics, Inc. ... Conference Call for the second quarter 2015 on Monday, ... Dr. Helen Torley , president and chief executive ... post-market, Halozyme will release financial results for the second ... live through the "Investors" section of Halozyme,s corporate website ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... is processed to get such derivatives as ethylbenzene, a precursor to styrene, used ... within the automotive industry for the production of tyres and other components. Thus, ...
(Date:8/3/2015)... E-QURE Corp. (OTCQB: EQUR), a ... Signal Therapy device ("BST Device"), a new and novel ... chronic wounds, today announced that the Company has signed ... specializing in medical devices, for the marketing and distribution ... 70 years old, sales, marketing and distribution company in ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... pumps to its comprehensive line of analytical laboratory equipment. With optimized features, such ... pumps provide a chemically resistant and maintenance-free solution for a broad range of ...
Breaking Biology Technology:Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Sterlitech Launches New Line of Vacuum Pumps 2
... Madison, Wis. -- Rita Colwell, former director of ... Pollution and Human Health" at 5:30 p.m. Monday, Oct. ... of Wisconsin-Madison's Memorial Union. , ,Colwell headed the NSF ... Inc., and is a distinguished professor at the University ...
... Wis. -- Three Wisconsin businesses will receive funding ... Commerce Technology Assistance Grant (TAG) and Technology Venture Fund ... , SonoPlot, Inc. is a Madison company established in ... $100,000 TVF loan to purchase equipment and develop a ...
... help of new silicon-based compounds, scientists - and patients ... the tiny lithium batteries used in implantable devices to ... lithium battery is the workhorse of implantable devices, which ... the central nervous system make critical connections in, for ...
Cached Biology Technology:New battery technology helps stimulate nerves 2New battery technology helps stimulate nerves 3
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... $5 million National Science Foundation (NSF) grant to upgrade ... Owens Valley Solar Array (OVSA) http://www.ovsa.njit.edu/ ... is expected to help scientists better understand the nature ... the military. "Space weather incidents such as ...
... What:,Based on what we know about smoking, diet, ... estimate we could prevent approximately half of all ... Association for Cancer Research will host its Ninth ... Research at the Pennsylvania Convention Center, located in ...
... Bad Hofgastein, 6 October 2010 -- European patients are in ... medically assisted reproduction (MAR) treatment, experts from the European Society ... European Health Forum Gastein (EHFG). The EHFG is ... EU. This year it has attracted about 600 decision-makers from ...
Cached Biology News:$5 million NSF grant will upgrade and expand NJIT radio telescope array 2$5 million NSF grant will upgrade and expand NJIT radio telescope array 3Reproductive health: Checkerboard of infertility treatment in Europe 2Reproductive health: Checkerboard of infertility treatment in Europe 3
5-bromo-2'-deoxyuridine (BrdU) Cell Biology Cell Proliferation Bromodeoxyuridine (BrdU) and Related Products...
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
... J. Karn (1995) This volume ... and methods for the study of major ... reverse transcriptase, ribonuclease H, integrase and protease. ... binding assays; Tat and Rev assays; HIV/CD4 ...
Human Glypican 2 Biotinylated Affinity Purified PAb...
Biology Products: